Lumateperone-impurity is an imuprity of Lumateperone (ITI722, ITI-007; Caplyta), which is a dual 5HT2A receptor antagonist and dopamine receptor phosphoprotein modulator approved as an atypical antipsychotic in 2019 for the treatment of schizophrenia.

纯度：≥98%

CAS：313368-85-3